Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03088527

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast Clinical Trial

Official title:
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Clinical Trial Summary

The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.

Clinical Trial Description

This is a first in humans study that is designed to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03088527
Study type Interventional
Source Stemline Therapeutics, Inc.
Contact
Status Completed
Phase Phase 1
Start date October 23, 2017
Completion date September 24, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03165487 - Comparison of the Breast Tumor Microenvironment
Completed NCT02347449 - The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population N/A
Withdrawn NCT04088032 - Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer Early Phase 1
Completed NCT04483505 - Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Phase 1
Not yet recruiting NCT04088110 - Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer Phase 2
Completed NCT01617954 - PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score N/A
Completed NCT01589367 - Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Phase 2
Active, not recruiting NCT02109913 - Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane N/A
Active, not recruiting NCT02668666 - Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Phase 2
Not yet recruiting NCT03910712 - Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC Phase 2
Recruiting NCT04030507 - Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer N/A
Completed NCT03969121 - Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer Phase 3
Recruiting NCT06120283 - BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Phase 1
Completed NCT02248571 - Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Phase 4
Completed NCT03594578 - Prospective Thinking in Hormone-Responsive Breast Cancer N/A
Recruiting NCT06253195 - BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Phase 1
Not yet recruiting NCT02025712 - Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer Phase 2